BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22307026)

  • 1. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.
    Wendel M; Bazhenova L; Boshuizen R; Kolatkar A; Honnatti M; Cho EH; Marrinucci D; Sandhu A; Perricone A; Thistlethwaite P; Bethel K; Nieva J; Heuvel Mv; Kuhn P
    Phys Biol; 2012 Feb; 9(1):016005. PubMed ID: 22307026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
    Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
    J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.
    Nair VS; Keu KV; Luttgen MS; Kolatkar A; Vasanawala M; Kuschner W; Bethel K; Iagaru AH; Hoh C; Shrager JB; Loo BW; Bazhenova L; Nieva J; Gambhir SS; Kuhn P
    PLoS One; 2013; 8(7):e67733. PubMed ID: 23861795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.
    Marrinucci D; Bethel K; Kolatkar A; Luttgen MS; Malchiodi M; Baehring F; Voigt K; Lazar D; Nieva J; Bazhenova L; Ko AH; Korn WM; Schram E; Coward M; Yang X; Metzner T; Lamy R; Honnatti M; Yoshioka C; Kunken J; Petrova Y; Sok D; Nelson D; Kuhn P
    Phys Biol; 2012 Feb; 9(1):016003. PubMed ID: 22306768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis.
    Chinniah C; Aguarin L; Cheng P; Decesaris C; Cutillo A; Berman AT; Frick M; Doucette A; Cengel KA; Levin W; Hahn S; Dorsey JF; Simone CB; Kao GD
    Clin Lung Cancer; 2019 Sep; 20(5):384-390.e2. PubMed ID: 31221522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis.
    Nieva J; Wendel M; Luttgen MS; Marrinucci D; Bazhenova L; Kolatkar A; Santala R; Whittenberger B; Burke J; Torrey M; Bethel K; Kuhn P
    Phys Biol; 2012 Feb; 9(1):016004. PubMed ID: 22306961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment.
    Wei T; Zhu D; Yang Y; Yuan G; Xie H; Shen R
    PLoS One; 2019; 14(7):e0219129. PubMed ID: 31344053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
    Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
    PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Lindsay CR; Blackhall FH; Carmel A; Fernandez-Gutierrez F; Gazzaniga P; Groen HJM; Hiltermann TJN; Krebs MG; Loges S; López-López R; Muinelo-Romay L; Pantel K; Priest L; Riethdorf S; Rossi E; Terstappen L; Wikman H; Soria JC; Farace F; Renehan A; Dive C; Besse B; Michiels S
    Eur J Cancer; 2019 Aug; 117():60-68. PubMed ID: 31254940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
    Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
    PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.
    Chen X; Wang X; He H; Liu Z; Hu JF; Li W
    PLoS One; 2015; 10(5):e0126276. PubMed ID: 25996878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
    Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
    Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR.
    Lou J; Ben S; Yang G; Liang X; Wang X; Ni S; Han B
    PLoS One; 2013; 8(12):e80458. PubMed ID: 24324600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
    Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
    BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
    Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
    Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
    Rieckmann LM; Spohn M; Ruff L; Agorku D; Becker L; Borchers A; Krause J; O'Reilly R; Hille J; Velthaus-Rusik JL; Beumer N; Günther A; Willnow L; Imbusch CD; Iglauer P; Simon R; Franzenburg S; Winter H; Thomas M; Bokemeyer C; Gagliani N; Krebs CF; Sprick M; Hardt O; Riethdorf S; Trumpp A; Stoecklein NH; Peine S; Rosenstiel P; Pantel K; Loges S; Janning M
    Mol Cancer; 2024 May; 23(1):93. PubMed ID: 38720314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.